CKD 516

Drug Profile

CKD 516

Alternative Names: CKD-516; NOV 1204; NOV-120401

Latest Information Update: 08 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Nov 2017 CKD 516 is still in phase I trials for Solid tumours in USA (IV, Injection) (National OncoVenture pipeline, November 2017)
  • 01 Dec 2016 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in South Korea (PO) (NCT03076957)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top